{"id":"W2133654917","doi":"10.1186/1756-8722-6-46","title":"A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine; Sorafenib; Rash; Diffuse large B-cell lymphoma; Hematology; Lymphoma; Oncology; Progression-free survival; Neutropenia; Overall survival; Gastroenterology; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001203276,0.0004783835,0.003036121,0.0007304479,0.0001546284,0.00001550128,0.0003732643,0.0004279757,0.0002716731],"category_scores_gemma":[0.0002151616,0.0003454899,0.000246171,0.000383327,0.0002022713,0.0002931754,0.0002552272,0.0004911933,0.0000516801],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001206622,"about_ca_system_score_gemma":0.001328717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003759552,"about_ca_topic_score_gemma":0.004004176,"domain_scores_codex":[0.9942902,0.001676837,0.002265452,0.0005519429,0.0005117157,0.0007038862],"domain_scores_gemma":[0.995889,0.0006682798,0.00159426,0.0005185479,0.0008716604,0.0004582233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.004150019,0.6607412,0.2824654,0.00004730021,0.0008495133,0.007352568,0.02057549,0.000002606289,0.0007305024,0.000112706,0.0009908584,0.02198188],"study_design_scores_gemma":[0.3637734,0.4869265,0.07798111,0.0001313096,0.001353081,0.0050697,0.0596419,0.0001977814,0.0009245102,0.00008868807,0.003556651,0.0003553229],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937851,0.001134003,0.00001917512,0.0009382166,0.0007369147,0.002650836,0.000008622043,0.00001906438,0.00070806],"genre_scores_gemma":[0.9985264,0.0001498512,0.0003644864,0.0003566664,0.0001475147,0.0003195198,0.00001102983,0.00004117775,0.00008334717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3596234,"threshold_uncertainty_score":0.9998997,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02826236165496909,"score_gpt":0.3575336845043388,"score_spread":0.3292713228493697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}